Drug: |
SF1126 |
|||
---|---|---|---|---|
Trial: |
A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Tumors |
|||
Conditions: | Solid Tumors | |||
Trial Status: |
Ongoing, but not recruiting |
Indiana University Simon Cancer Center535 Barnhill Drive |
Principal Investigator: |
E. Gabriela Chiorean, MD |
---|---|
Contact: |
Mary Jane Waddell, RN, CCRC 317-274-7119 mjwaddell@iupui.edu Jennifer M Funke, MS 317-278-0328 jmfunke@iupui.ed |
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
Indiana University Simon Cancer Center Website: |
http://cancer.iu.edu/cancer/trials/findtrials.php?category=disease |
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.